Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Molecular Partners (MOLN) is deepening its focus on targeted radiotherapy and plans to reduce its workforce by up to approximately 44%. The proposed reduction covers no more than 55 positions, with employee consultation underway. Implementation is expected by Q2 2027, with cost reductions fully effective early in H2 2027.
Dosing continues in the fully recruited second dose level of the MP0712 Phase 1/2a study. No dose-limiting events occurred in dose level 1; adverse events reported to date were mild to moderate and transient. Initial safety data are due in December 2026, with efficacy data expected in 2027.
Cash and cash equivalents were CHF 57.5 million at September 30, 2026. The company expects funding to last into late 2027 under current operating assumptions and forecasts 2026 operating expenses of CHF 50–55 million at constant exchange rates. Other radiotherapy programs continue advancing.
Molecular Partners (MOLN) selected MP0730 as its lead CD70-targeting Radio-DARPin candidate, adding a third program to its targeted alpha radiotherapy pipeline.
The company expects a first-in-human program to start mid-2027. Preclinical data presented on October 1, 2026, showed sustained tumor uptake in tumor-bearing mice relative to healthy tissues, including kidney, liver and blood. These results concern distribution in mice, not human treatment outcomes. CD70 is overexpressed in clear cell renal cell carcinoma, a type of kidney cancer, and other cancers; its expression is maintained in metastases and limited in healthy tissues.
Molecular Partners (SIX, NASDAQ: MOLN) reported H1 2026 results and pipeline progress, led by DLL3-targeting Radio-DARPin MP0712 for small cell lung cancer. The U.S. Phase 1/2a trial fully recruited cohort 1 at 75 MBq with no dose-limiting toxicities and only transient grade 1–2 adverse events, enabling escalation to cohort 2 at 105 MBq. Initial clinical data are expected in 2026 and a broader safety/efficacy dataset in 2027.
The company expanded its radio-oncology portfolio by selecting CD70 as a third target for clear cell renal cell carcinoma and other tumors, with IND-enabling work starting H2 2026 and clinical entry planned for 2027. Immune cell engager programs advanced, including MP0317 in a randomized Phase 2 cholangiocarcinoma study and fully recruited dose escalation for MP0533 in AML.
H1 2026 financials showed no revenue, operating expenses of CHF 27.0 million and a net loss of CHF 26.7 million, both improved versus H1 2025. Cash and cash equivalents were CHF 67.9 million, with the company expecting funding into late 2027 and maintaining 2026 operating expense guidance of CHF 45–55 million.
Molecular Partners (SIX/NASDAQ: MOLN) reported clinical progress for MP0317 in the randomized Phase 2 TACTIC trial in first-line advanced biliary tract carcinoma (cholangiocarcinoma). The investigator-initiated French study plans to enroll 75 patients (2:1 randomization; 50 experimental, 25 control) comparing MP0317 plus standard-of-care durvalumab and gemcitabine-cisplatin chemotherapy versus standard-of-care alone.
Nine expert sites are activated and patients are being treated. A data update is expected in 2027, with study completion targeted for 2028. A trial-in-progress poster has been accepted for the ESMO Congress 2026. MP0317, a FAP-localized CD40 agonist, previously showed tumor-localized CD40 activation and tumor microenvironment remodeling in a completed 46-patient Phase 1 study, whose results were published in Nature Cancer in 2026.
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) is presenting new data on its bispecific and multispecific Radio-DARPins at the Gordon Research Conference on Radionuclide Theranostics for the Management of Cancer in Newry, Maine, on July 15, 2026. The talk, given by SVP Targeted Radio Therapeutics Daniel Steiner, focuses on designing DARPins that align binding properties, half-life, and biodistribution with tumor and disease biology to overcome target limitations in radioligand therapy.
The company highlights mono-targeting and multispecific formats, including bispecific constructs and 2-in-1 DuoDARPins, intended to address tumor heterogeneity and co-expressed tumor targets. Lead candidate MP0712 (DLL3; with Orano Med) is in a US Phase 1/2a trial, while MP0726 (MSLN) is progressing toward first human imaging and a third Radio-DARPin program is planned for 2026.
Molecular Partners (NASDAQ:MOLN) reported pipeline progress for its targeted alpha Radio-DARPin therapeutics. The Phase 1/2a US trial of MP0712, a 212Pb-based DLL3-targeted candidate for small cell lung and neuroendocrine cancers, is dosing patients, with initial data expected in the coming months and broader efficacy readout in 2027.
Compassionate use work with 225Ac/177Lu DLL3 Radio-DARPin MP0714 has started in South Africa. Second candidate MP0726 targeting MSLN is planned for first-in-human imaging in H2 2026. The company also plans two IND filings in 2027 and a new RDT target nomination in H2 2026.
Molecular Partners (SIX:MOLN; NASDAQ:MOLN) and Orano Med announced that first patients have been dosed in a US multicenter Phase 1/2a trial of DLL3-targeting, 212Pb-labelled Radio-DARPin MP0712.
The study uses a matched-pair imaging/therapy design, is recruiting at five US sites, and plans up to four dose levels. Initial data are expected in the coming months, with comprehensive safety and efficacy readout in 2027.
Molecular Partners (NASDAQ:MOLN) will present trial-in-progress posters on its DLL3-targeting radio-DARPin MP0712 at ASCO 2026 in Chicago and SNMMI 2026 in Los Angeles.
The ongoing US Phase 1/2a trial is dosing the first cohort, with initial clinical data expected in 2026.
Molecular Partners (NASDAQ:MOLN), a clinical-stage biotech focused on DARPin therapeutics, will participate in TD Cowen’s 7th Annual Oncology Innovation Summit on May 27, 2026, at 11:30am ET.
The fireside chat will be webcast and accessible via the company’s website under the investors tab.
Molecular Partners (SIX: MOLN, NASDAQ: MOLN) reported Q1 2026 highlights, including initiation of clinical studies for MP0712 and MP0317 and progress across its DARPin pipeline.
The company held CHF 79 million in cash and short-term deposits as of March 31, 2026, with runway into late 2027.